Navigation Links
Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline

Research by CMR Shows Revenue Derived from New Products Launched within the

Last Five Years has Dropped to Just 16% of Total Revenue in 2006

PHILADELPHIA, Aug. 15 /PRNewswire-FirstCall/ -- Thomson Scientific, part of The Thomson Corporation (NYSE: TOC; TSX: TOC) and leading provider of information solutions to the worldwide research and business communities, today issued its quarterly The Ones-to-Watch report, providing expert insight into the five most promising drugs to enter each new phase of clinical development between April and June 2007.

"This quarter's most promising drugs all have significant market potential and are associated with diseases and conditions that impact countless numbers of individuals," said Peter Robins, PhD, and editorial content manager, Thomson Scientific. "These important clinical developments are highly encouraging for innovation-based companies in a period when many pharmaceutical products are coming toward the end of their patent protection."

New research from CMR, a Thomson company, shows that revenue derived from new products (those launched within the last five years) dropped to just 16% of total revenue in 2006. And although the cost of research and development continues to rise, there is no sign of a sustained upturn in the number of new products reaching the market.

Which are the Ones-to-Watch this Quarter?

Topping this quarter's approval list is Novartis Vaccines & Diagnostics' Optaflu(R), a vaccine for influenza derived from a novel, proprietary cell line. Approved for use in the EU in June 2007, Novartis plans to file for US approval of Optaflu in 2008.

Second on our list is Wyeth, which is marketing Lybrel(TM) -- a combination of Levonorgestrel and ethinyl estradiol in a daily oral tablet which eliminates the menstrual cycle and is being trialed as a potential treatment for severe premenstrual syndromes.

Third is a drug launched in Japan in June 2007 for the treatment of incontinence and pollakiuria (frequent urination) under the name Staybla(R). Urinary incontinence is particularly prevalent in men and usually associated with aging. Where the problem is an overactive bladder, patients may benefit from the M1 and M3 muscarinic receptor imidafenacin, developed by Kyorin Pharmaceutical, Ono Pharmaceutical and LG Life Sciences.

Fourth is a drug for one of the most severe forms of epilepsy (Lennox- Gastaut Syndrome or LGS), affecting approximately 5% of the children who have the disease. Eisai's rufinamide, licensed from Novartis, is the first drug approved in the EU specifically for LGS. Eisai launched rufinamide in Germany, Australia and Scandinavia in June 2007 under the name Inovelon(TM). US filing is in process.

Finally for this section this quarter, Torisel(TM) is the brand name of temsirolimus, an analog of the mTOR inhibitor sirolimus (rapamycin) developed by Wyeth Research for the oral treatment of advanced renal cell carcinoma (RRC). Having received FDA approval in May 2007, the drug is now available to patients in the US, while approval is pending in the EU.

Following are the top five drugs in each category of phase changes:

The Five Most Promising Drugs Entering Phase III Trials

- trazodone, (Depression), Labopharm

- pimavanserin, (Schizophrenia), ACADIA Pharmaceuticals

- salmon calcitonin, (Osteoporosis/Paget's disease), Novartis/Nordic


- Generx(TM), (Coronary artery disease), Cardium Therapeutics

- fenofibrate and pravastatin, (Mixed dyslipidemia), Sciele

Pharma/Galephar PR

The Five Most Promising Drugs Entering Phase II Trials

- VSF-173, (Excessive sleepiness), Vanda Pharmaceuticals

- APD-125, (Insomnia), Arena

- Neugranin(TM), (Chemotherapy-induced neutropenia), CoGenesys

- Hepaconda(R) , (Hepatitis C), Giaconda

- GRC-6211, (Pain), Glenmark

The Five Most Promising Drugs Entering Phase I Trials

- Ad35 HIV-ENvA, (HIV infection), GenVec/NIAID Vaccine Research Center

- nestorone and estradiol (transdermal gel), (Female contraception),

Antares/Population Council

- Fluvacc, (Influenza), Avir Green Hills Biotechnology

- insulin oral gel capsule, (Diabetes), Oramed

- trodusquemine, (Obesity), Ganaera

About This Quarterly Report:

Data for this report was compiled and analyzed using Thomson Pharma(R), a comprehensive global pharmaceutical information solution that covers the entire drug discovery and development pipeline. Its competitive intelligence and strategic data can justify and speed decision-making, facilitate more focused collaboration, and encourage innovation.

For a copy of the full report with analysis, visit:

About The Thomson Corporation

The Thomson Corporation ( is a global leader in providing essential electronic workflow solutions to business and professional customers. With operational headquarters in Stamford, Conn., Thomson provides value-added information, software tools and applications to professionals in the fields of law, tax, accounting, financial services, scientific research and healthcare. The Corporation's common shares are listed on the New York and Toronto stock exchanges (NYSE: TOC; TSX: TOC).

Thomson Scientific is a business of The Thomson Corporation. Its information solutions assist professionals at every stage of research and development-from discovery to analysis to product development and distribution. Thomson Scientific information solutions can be found at

SOURCE Thomson Scientific

Copyright©2007 PR Newswire.

Related medicine technology :

1. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
2. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
3. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
6. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
7. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
8. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
9. Inspire Announces Presentations at Two European Scientific Conferences
10. HepaLife Announces Scientific Presentation of PBS-1 Cell Line at International Influenza Meeting
11. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
Post Your Comments:
(Date:10/8/2015)... Oct. 8, 2015  Trovagene, Inc., (NASDAQ:   ... announced the presentation of results from a field ... Cancer Monitoring SM (PCM) platform to accurately ... physicians to determine appropriate therapy for patients. ... Trovagene is delivering the results today in an ...
(Date:10/8/2015)... New York , October 8, 2015 ... Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - ... was valued at USD 2.63 billion in 2013 and is ... to 2022 to reach USD 4.00 billion in 2022. ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 ...
(Date:10/8/2015)... DUBLIN , Oct. 08 2015 /PRNewswire/ ... announced the addition of the "Natural ... Life Sciences Industry by Type (Rule-Based, Statistical, ... Europe, Asia-Pacific, Middle East and Africa, Latin ... report to their offering. --> ...
Breaking Medicine Technology:
... 2011 Actavis Group, the international generic pharmaceuticals company, today ... a binding letter of intent (LOI) with QRxPharma Limited (ASX: ... United States.  Under the terms of the ... IR, a patented 3:2 ratio fixed dose combination of morphine ...
...  QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today execution ... for the formation of a strategic partnership to commercialise MoxDuo ... IR is a patented 3:2 ratio fixed dose combination of ... Group, hf a privately held company based in Europe with ...
Cached Medicine Technology:
(Date:10/10/2015)... , ... October 10, 2015 , ... The sixth annual ... on the growth of cybercrime costs for US companies. The New York Times broke ... 6th. With averages showing increases hovering around 20% among the companies surveyed, it only ...
(Date:10/10/2015)... Arbor, MI (PRWEB) , ... October 10, 2015 , ... ... City, MO. , On the heels of the release of the Institute of ... of tools, and their integration with Cerner solutions that assist healthcare providers and consumers ...
(Date:10/9/2015)... ... October 09, 2015 , ... The American ... Dean for Graduate Medical Education J. Michael Finley, DO, as the recipient of ... selected for his impact on graduate medical education opportunities for osteopathic residents, and ...
(Date:10/9/2015)... ... October 09, 2015 , ... A new health tool ... Aid, is now available online ( ) – just in time for the ... officially begins in October. However, for many in the U.S., the real start of ...
(Date:10/9/2015)... , ... October 09, 2015 , ... ... a special promotion on Invisalign, the orthodontic system that uses clear, plastic aligners. ... are almost invisible against the teeth, which allow patients to complete treatment in ...
Breaking Medicine News(10 mins):
... (HealthDay News) -- Drinking too much alcohol can lead to ... the most common cause of HIV infection and finding ways ... health efforts to prevent HIV/AIDS. Alcohol use has long ... whether unsafe sex associated with alcohol use actually led to ...
... MONDAY, Dec. 12 (HealthDay News) -- Breast cancer survivors ... treatment with radiation and/or chemotherapy, a new study says. ... and treatment-specific ways that these cancer therapies impair cancer ... Moffitt Cancer Center and Research Institute in Tampa, Fla., ...
... , Researchers at the Norwegian University of Life Sciences ... new method for detailed analyses of electrical activity in ... can help doctors and researchers to better interpret ... considerable steps forward in terms of interpreting for example ...
... has found that alcohol consumption directly impacts a person,s intention to ... the stronger becomes your intention to engage in unsafe sex. ... infection, and it is a main risk factor for the global ... prevent unsafe sex, HIV incidence in most high income countries (such ...
... leukemia patients, own infection-fighting cells appears to protect ... with fludarabine-based chemotherapy, according to new research from ... of Pennsylvania. The new process is a step ... from the commonly prescribed drug, which improves progression-free ...
... Researchers at the Stanford University School of Medicine report ... physical force contributes to scarring in mice. "Our ... the mechanical environment can directly increase inflammation, which is ... and associate chair of surgery. Mice genetically engineered ...
Cached Medicine News:
Optipress II Automated Blood Component Extractor for the standardized separation of whole blood into high purity individual components...
... Distriman is a ... that is designed to ... used with Gilson DistriTip ... polypropylene syringes with level ...
The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
... Plus, a handheld manual dispenser, is ideal ... long series pipetting. Its increased volume selection ... research tasks, and its smooth handling reduces ... The nine Combitips allow a wider range ...
Medicine Products: